Skip to main content

enGene Therapeutics Inc 8-K, filed Nov 12, 2026

enGene Therapeutics Inc. (ENGN)

8-K 2026-11-12 For: 2026-11-11
View Original
Added on November 12, 2026

About this 8-K

enGene Therapeutics Inc filed this 8-K on November 12, 2026, reporting on events of November 11, 2026.

enGene Therapeutics Inc. reported 56% complete response at any time for detalimogene in Cohort 1 of Phase 2 LEGEND, with 43% Kaplan-Meier estimated duration of response of at least 12 months and plans to initiate BLA filing in 4Q 2026. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 7.01: Regulation FD disclosure
  • Item 8.01: Other events
  • Item 9.01: Financial statements and exhibits